Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y
Front Cell Dev Biol. 2025; 13:1523958.
PMID: 39968176
PMC: 11833226.
DOI: 10.3389/fcell.2025.1523958.
Peris-Diaz M, Krezel A, Barran P
Commun Chem. 2025; 8(1):13.
PMID: 39814824
PMC: 11736120.
DOI: 10.1038/s42004-024-01395-w.
Ju M, Tong W, Bi J, Zeng X, Qi A, Sun M
Adv Sci (Weinh). 2025; 12(8):e2413607.
PMID: 39755930
PMC: 11848574.
DOI: 10.1002/advs.202413607.
Yousef A, Fang L, Heidari M, Kranrod J, Seubert J
Front Pharmacol. 2024; 15:1486717.
PMID: 39703395
PMC: 11655241.
DOI: 10.3389/fphar.2024.1486717.
Zhao Y, Wang Y, Xia Q, He H, Mao Q, Dong H
Cancer Control. 2024; 31:10732748241302865.
PMID: 39612472
PMC: 11607764.
DOI: 10.1177/10732748241302865.
How does p53 work? Regulation by the intrinsically disordered domains.
Dyson H, Wright P
Trends Biochem Sci. 2024; 50(1):9-17.
PMID: 39578215
PMC: 11698644.
DOI: 10.1016/j.tibs.2024.10.009.
What have we learned about TP53-mutated acute myeloid leukemia?.
Shahzad M, Amin M, Daver N, Shah M, Hiwase D, Arber D
Blood Cancer J. 2024; 14(1):202.
PMID: 39562552
PMC: 11576745.
DOI: 10.1038/s41408-024-01186-5.
FXR deficiency induced ferroptosis via modulation of the CBP-dependent p53 acetylation to suppress breast cancer growth and metastasis.
Huang P, Zhao H, Dai H, Li J, Pan X, Pan W
Cell Death Dis. 2024; 15(11):826.
PMID: 39543094
PMC: 11564727.
DOI: 10.1038/s41419-024-07222-3.
Nitric Oxide Signaling and Sensing in Age-Related Diseases.
Mazuryk O, Gurgul I, Oszajca M, Polaczek J, Kieca K, Bieszczad-Zak E
Antioxidants (Basel). 2024; 13(10).
PMID: 39456466
PMC: 11504650.
DOI: 10.3390/antiox13101213.
The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors.
Sui Q, Yang H, Hu Z, Jin X, Chen Z, Jiang W
Pharm Res. 2024; 41(11):2143-2159.
PMID: 39455505
DOI: 10.1007/s11095-024-03783-2.
TRIM33 promotes glycolysis through regulating P53 K48-linked ubiquitination to promote esophageal squamous cell carcinoma growth.
Xia T, Meng L, Xu G, Sun H, Chen H
Cell Death Dis. 2024; 15(10):740.
PMID: 39389957
PMC: 11467421.
DOI: 10.1038/s41419-024-07137-z.
Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.
Chen L, Singha Roy S, Jadhav A, Wang W, Chen P, Bishop T
ACS Chem Biol. 2024; 19(9):1918-1929.
PMID: 39250704
PMC: 11421428.
DOI: 10.1021/acschembio.4c00438.
Role of UFMylation in tumorigenesis and cancer immunotherapy.
Ding L, Jiang X, Li T, Wang S
Front Immunol. 2024; 15:1454823.
PMID: 39247188
PMC: 11377280.
DOI: 10.3389/fimmu.2024.1454823.
Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels.
Kriuchkovskaia V, Eames E, Riggins R, Harley B
Adv Healthc Mater. 2024; 13(27):e2400779.
PMID: 39030879
PMC: 11518645.
DOI: 10.1002/adhm.202400779.
Exploring the Functional Landscape of the p53 Regulatory Domain: The Stabilizing Role of Post-Translational Modifications.
Bakker M, Svensson O, So Rensen H, Skepo M
J Chem Theory Comput. 2024; 20(14):5842-5853.
PMID: 38973087
PMC: 11270737.
DOI: 10.1021/acs.jctc.4c00570.
YTHDC1 mA-dependent and mA-independent functions converge to preserve the DNA damage response.
Elvira-Blazquez D, Fernandez-Justel J, Arcas A, Statello L, Goni E, Gonzalez J
EMBO J. 2024; 43(16):3494-3522.
PMID: 38951610
PMC: 11329685.
DOI: 10.1038/s44318-024-00153-x.
The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.
Bai B, An X, Qu Q, Liu X, Liu Y, Wei L
Clin Transl Oncol. 2024; 26(12):3236-3245.
PMID: 38872053
DOI: 10.1007/s12094-024-03533-1.
Unveiling the Mechanisms of EGCG-p53 Interactions through Molecular Dynamics Simulations.
Bahena Culhuac E, Bello M
ACS Omega. 2024; 9(18):20066-20085.
PMID: 38737068
PMC: 11080030.
DOI: 10.1021/acsomega.3c10523.
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues.
Valles-Marti A, de Goeij-de Haas R, Henneman A, Piersma S, Pham T, Knol J
Mol Oncol. 2024; 18(8):2020-2041.
PMID: 38650175
PMC: 11306541.
DOI: 10.1002/1878-0261.13625.
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study.
Chang Y, Kuo H, Chen T, Chen J, Lim L, Wang K
J Gynecol Oncol. 2024; 35(6):e78.
PMID: 38576345
PMC: 11543261.
DOI: 10.3802/jgo.2024.35.e78.